Latest quarter
West Pharmaceutical Services reported Q3 FY2026 revenue of $874.5 million, above the consensus estimate of $825.9 million. Adjusted earnings per share were $2.66, above the consensus of $2.18. Revenue also exceeded the company’s own quarterly guidance of $820.0 million to $835.0 million.
Revenue rose from $804.6 million a year earlier, and diluted earnings per share increased to $3.02 from $1.92. West’s filing said volume, product mix and price increases contributed to sales growth, while currency translation and lower SmartDose product revenue following the product-line sale reduced it.
The filing attributed growth in Proprietary Products to demand for high-value components used in biologics and GLP-1 products, as well as price increases. West Vantage sales fell as a continuous glucose monitoring contract expired, partly offset by price increases and sales of self-injection devices and components.
West reported gross margin of 39.7%, up from 36.6% a year earlier, and operating margin of 30.6%, compared with 20.8%. The filing said the company recorded a $55.7 million net gain on the SmartDose asset sale. Free cash flow rose to $150.4 million from $133.9 million.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $874.5 million | $804.6 million | 8.69% |
| Diluted EPS | $3.02 | $1.92 | 57.4% |
| Gross margin | 39.7% | 36.6% | 3.1 percentage points |
| Operating margin | 30.6% | 20.8% | 9.7 percentage points |
| Free cash flow | $150.4 million | $133.9 million | 12.3% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $2.66 | $2.18 | Beat by 22.0% |
| Revenue | $874.5 million | $825.9 million | Beat by 5.88% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
| Against its own guidance | For | Guided | Reported | Result |
|---|---|---|---|---|
| Revenue | Q3 FY2026 | $820.0 million–$835.0 million | $874.5 million | Above the guide |
What management said on the call
On the earnings call, CEO Michele Lagarde said demand for both GLP-1 and other components, along with customer upgrades to higher-value products, drove growth in Proprietary Products. CFO Bob McMahon said high-value components benefited from biologics demand and a shift toward those products. He added that European Annex 1 regulations were driving upgrades and that West was seeing signs of upgrade activity in other regions.
McMahon said price contributed just over 4 percentage points of quarterly growth. Asked whether that pace would continue, Lagarde said the company’s long-term pricing assumption remained 2% to 3%, although pricing was ahead of that range this year.
McMahon attributed the increase in gross margin to product mix, pricing and plant performance. Asked whether the quarter established a new margin floor, he said it did not, but pointed to opportunities for continued expansion through mix and efficiency. He also said adjusted operating margin rose to 25.3%, helped by gross margin and the ability to spread selling, general and administrative costs over higher sales.
Lagarde said she wants closer customer relationships to improve demand planning and adoption of West’s innovations. She also described continuous improvement as a priority, including automation and digitization to increase output from existing capacity. McMahon said West is starting investments in high-value finishing capacity in Europe and the U.S.; in response to a capacity question, he said existing capacity can support current demand.
On West Vantage, McMahon said new program sales were more than offset by the roll-off of a continuous glucose monitoring program. He added that the business recovered revenue deferred by the cyber incident during the quarter. Looking ahead, he said high-value device growth in Q4 was not expected to match Q3, citing the prior-year comparison. Asked about revenue mix, McMahon said he had no specific target, but expected high-value products to grow faster than the company overall.
Guidance
McMahon said West raised its FY2026 revenue outlook to $3.41 to $3.42 billion from $3.345 billion to $3.38 billion. The company now expects organic sales growth of 11.3% to 11.6%, compared with its prior range of 10% to 11%.
West raised its full-year adjusted EPS guidance to $9.38 to $9.48 from $8.85 to $9.05. The company reduced its capital spending outlook to $215 million to $220 million from $250 million to $275 million.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Revenue, Hvp Devices | Q4 FY2026 | West does not expect HVP device growth in Q4 FY2026 to match its Q3 growth. | — | — |
| Units | FY2026 | 40,000,000,000 | — | — |
| Tax rate | FY2026 | 18.0% | — | New |
| Operating margin, Year Over Year Change | FY2026 | 3.00% | — | New |
| EPS, non-GAAP | FY2026 | $9.38–$9.48 | $8.85–$9.05 | Raised |
| Revenue, Hvp Components | Q4 FY2026 | West expects double-digit growth in HVP components in Q4 FY2026. | — | — |
| Revenue growth, Non Gaap Organic Growth | Q4 FY2026 | 6.00%–7.00% | — | New |
| Revenue | Q4 FY2026 | $820.0 million–$830.0 million | Q3 FY2026: $820.0 million–$835.0 million; reported $874.5 million | Held |
| Revenue growth, Non Gaap Organic Growth | FY2026 | 11.3%–11.6% | — | New |
| Revenue | FY2026 | $3.4 billion–$3.4 billion | $3.3 billion–$3.4 billion | Raised |
| Free cash flow | Q4 FY2026 | West expects continued improvement in free cash flow in Q4 FY2026. | — | — |
| Capex | FY2026 | $215.0 million–$220.0 million | $250.0 million–$275.0 million | Cut |
| EPS, GAAP | FY2026 | $9.31–$9.41 | $9.01–$9.26 | Raised |
| Revenue, Smartdose 3 5ml | Q4 FY2026 | West expects no additional SmartDose 3.5mL product sales in Q4 FY2026. | — | — |
| Revenue growth, Organic Growth | FY2026 | 11.3%–11.6% | 10.0%–11.0% | Raised |
| Revenue growth, Reported Growth | FY2026 | 8.80%–10.0% | — | New |
| Revenue, Reported | FY2026 | $3.3 billion–$3.4 billion | — | New |
| Revenue growth, Annex 1 Mix Shift | FY2026 | 2.00% | — | New |
| Operating margin, Smartdos 3 5 Divestiture | FY2026 | 0.50% | — | New |
| Operating margin | FY2026 | 2.00% | — | New |
| EPS, Adjusted Diluted | FY2026 | $8.85–$9.05 | — | New |
| Revenue growth, Organic | FY2026 | 10.0%–11.0% | — | New |